{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:23:19Z","timestamp":1792700599173,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejmech.2025.117644","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:27:37Z","timestamp":1744878457000},"page":"117644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Scaffold hopping-based structural modification of tranilast led to the identification of HNW005 as a promising NLRP3 inflammasome and URAT1 dual inhibitor for the treatment of gouty arthritis"],"prefix":"10.1016","volume":"292","author":[{"given":"Ming","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10287","key":"10.1016\/j.ejmech.2025.117644_bib1","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Gout. Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117644_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.semarthrit.2018.04.006","article-title":"Gout of the axial joint-A patient level systemic review","volume":"48","author":"Zhang","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117644_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101723","article-title":"Role of diet in hyperuricemia and gout","volume":"35","author":"Danve","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117644_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41584-018-0149-7","article-title":"Prevention and treatment of gout","volume":"15","author":"Stamp","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117644_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.rdc.2022.03.001","article-title":"Management and cure of gouty arthritis","volume":"48","author":"Keller","year":"2022","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117644_bib6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jsps.2022.04.013","article-title":"A review on benefits of quercetin in hyperuricemia and gouty arthritis","volume":"30","author":"Nutmakul","year":"2022","journal-title":"Saudi Pharm. J."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117644_bib7","first-page":"831","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer","year":"2014","journal-title":"Am. Fam. Physician"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117644_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026677","article-title":"Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejmech.2025.117644_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.925219","article-title":"Review of urate-lowering therapeutics: from the past to the future","volume":"13","author":"Jenkins","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117644_bib10","doi-asserted-by":"crossref","first-page":"19966","DOI":"10.1021\/acs.jmedchem.4c01260","article-title":"Recent progress and future perspectives on anti-hyperuricemic agents","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117644_bib11","doi-asserted-by":"crossref","first-page":"14474","DOI":"10.1021\/acs.jmedchem.3c01710","article-title":"Agents for the treatment of gout: current advances and future perspectives","volume":"66","author":"Zeng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117644_bib12","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1021\/acs.jmedchem.1c02057","article-title":"Discovery of novel bicyclic Imidazolopyridine-Containing human urate transporter 1 inhibitors as hypouricemic drug candidates with improved efficacy and favorable druggability","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117644_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/1060028018762103","article-title":"Lesinurad: a novel agent for management of chronic gout","volume":"52","author":"Haber","year":"2018","journal-title":"Ann. Pharmacother."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117644_bib14","doi-asserted-by":"crossref","first-page":"10829","DOI":"10.1021\/acs.jmedchem.0c00223","article-title":"Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability","volume":"63","author":"Zhao","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117644_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.291","article-title":"Uricosuric targets of tranilast","volume":"5","author":"Mandal","year":"2017","journal-title":"Pharmacol. res. perspectiv."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117644_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","article-title":"Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout","volume":"22","author":"Ishikawa","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117644_bib17","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1021\/acs.jmedchem.4c00136","article-title":"Discovery of a novel thienopyrimidine compound as a urate transporter 1 and glucose transporter 9 dual inhibitor with improved efficacy and favorable druggability","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117644_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425255.2023.2287477","article-title":"Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout","volume":"19","author":"Hou","year":"2023","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117644_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/phar.1788","article-title":"Gouty arthritis: a review of acute management and prevention","volume":"36","author":"Wilson","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117644_bib20","article-title":"Non-steroidal anti-inflammatory drugs for acute gout","volume":"12","author":"van Durme","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117644_bib21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11739-021-02654-7","article-title":"Colchicine efficacy and safety for the treatment of cardiovascular diseases","volume":"16","author":"Andreis","year":"2021","journal-title":"Intern. emerg. med."},{"key":"10.1016\/j.ejmech.2025.117644_bib22","article-title":"Role of NLRP3 in the pathogenesis and treatment of gout arthritis","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117644_bib23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/1756-185X.14205","article-title":"The current role of NLRP3 inflammasome polymorphism in gout susceptibility","volume":"24","author":"Clavijo-Cornejo","year":"2021","journal-title":"Int. j. rheum. dis."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117644_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4078\/jrd.2022.29.3.140","article-title":"The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout","volume":"29","author":"Kim","year":"2022","journal-title":"J. rheum. dis."},{"key":"10.1016\/j.ejmech.2025.117644_bib25","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117644_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121353119","article-title":"Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation","volume":"119","author":"Ohto","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117644_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117644_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"Elliott","year":"2015","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117644_bib29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117644_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117644_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040976","article-title":"NLRP3 inflammasome inhibitors in cardiovascular diseases","volume":"26","author":"Mezzaroma","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2025.117644_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117644_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","article-title":"The NLRP3 inflammasome: contributions to inflammation-related diseases","volume":"28","author":"Chen","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2025.117644_bib34","article-title":"Exosomes regulate NLRP3 inflammasome in diseases","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117644_bib35","doi-asserted-by":"crossref","first-page":"16141","DOI":"10.1021\/acs.jmedchem.3c01511","article-title":"Discovery of novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 inflammasome inhibitors targeting Colon as a potential therapy for colitis","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117644_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-Hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117644_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117644_bib38","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1021\/acs.jmedchem.4c00504","article-title":"Hit-to-Lead optimization of the natural product oridonin as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activity","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejmech.2025.117644_bib39","doi-asserted-by":"crossref","first-page":"18172","DOI":"10.1021\/jacs.4c06538","article-title":"NLRP3 inflammasome inhibitors discovered from spatially restricted crosstalk of biosynthetic pathways","volume":"146","author":"Zhang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117644_bib40","doi-asserted-by":"crossref","first-page":"11985","DOI":"10.1021\/acs.jmedchem.2c00523","article-title":"Discovery of a novel oral proteasome inhibitor to block NLRP3 inflammasome activation with anti-inflammation activity","volume":"65","author":"Wu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117644_bib41","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/acs.jcim.0c01146","article-title":"Ligand entropy is hard but should not be ignored","volume":"60","author":"Winkler","year":"2020","journal-title":"J. Chem. Inf. Model."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117644_bib42","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117644_bib43","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1021\/acs.jmedchem.0c01457","article-title":"N-Trifluoromethyl amines and azoles: an underexplored functional group in the medicinal chemist's toolbox","volume":"63","author":"Schiesser","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117644_bib44","doi-asserted-by":"crossref","first-page":"8917","DOI":"10.1038\/s41467-024-53271-9","article-title":"N-Halosuccinimide enables Cascade oxidative trifluorination and halogenative cyclization of tryptamine-derived isocyanides","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117644_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.117644_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.toxicon.2017.10.016","article-title":"Exotoxins and endotoxins: inducers of inflammatory cytokines","volume":"149","author":"Cavaillon","year":"2018","journal-title":"Toxicon : off. j. Int. Soc. Toxinology"},{"key":"10.1016\/j.ejmech.2025.117644_bib47","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3389\/fimmu.2019.03009","article-title":"Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management","volume":"10","author":"Vanderwall","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117644_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrrheum.2013.160","article-title":"Role of cytokines in intervertebral disc degeneration: pain and disc content","volume":"10","author":"Risbud","year":"2014","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:45:09Z","timestamp":1753865109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"alternative-id":["S022352342500409X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117644","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scaffold hopping-based structural modification of tranilast led to the identification of HNW005 as a promising NLRP3 inflammasome and URAT1 dual inhibitor for the treatment of gouty arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117644"}}